Understanding the Relationship Between Corneal Nerve Function and the Ocular Surface (CE Webcast)
Activity Description and Purpose
Corneal nerve dysfunction is the underlying cause of neurotrophic keratitis and has an etiologic role in the pathogenesis of dry eye disease and its symptoms. Knowledge of the mechanisms has implications for establishing a diagnosis in patients with ocular surface disease and using neuroregenerative therapy. This educational activity is based on the proceedings of a live CME/CE symposium that took place on Monday, May 2, 2022. The desired results of this activity are to increase understanding of the role of the corneal nerve in ocular surface health and disease as a foundation for enabling proper diagnosis and for selecting optimal treatment.
This educational activity is intended for optometrists.
After completing this activity, participants will be better able to:
- Review the role of the corneal nerve in maintaining ocular surface homeostasis
- Identify signs and symptoms of ocular disease related to corneal nerve dysfunction
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
|Stephen C. Pflugfelder, MD (Chair)|
Professor of Ophthalmology
James and Margaret Elkins Chair
Baylor College of Medicine
|Paul Karpecki, OD|
University of Pikeville School of Optometry
Director, Cornea and External Disease
Kentucky Eye Institute and Gaddie Eye Centers
|Melissa Toyos, MD|
Partner and Director of Research
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company. All relevant relationships with ineligible companies have been mitigated.
Paul Karpecki, OD, is a consultant for AbbVie Inc, Akorn, Inc, Alcon, Aldeyra Therapeutics, Allergan, Ametek, Inc, Atlas Medical GmbH, Avellino, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bio-Tissue, BlephEx, Bruno Vision, Cambium Medical Technologies, Dompé US, Inc, Gobiquity, Haag-Streit Group, Hilco Vision, Icare USA Inc, Imprimis Pharmaceuticals, Inc, Kala Pharmaceuticals, Kiora Pharmaceuticals, Inc, Konan Medical USA, Inc, Lentechs, Neurolens, Novartis Pharmaceuticals Corporation, OASIS Medical, OCULUS, Inc, OCuSOFT Inc, Optase, Oyster Point Pharma, Inc, Rendia, Inc, RVL Pharmaceuticals, Inc, RxSIGHT, ScienceBased Health, Sentiss Pharma Pvt Ltd, Sight Sciences, StepWise Medical, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, Visant Medical, Inc, Vital Tears LLC, and Zeiss; is an advisory board member of AstaReal, Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Johnson & Johnson Vision Care, Inc, and Mallinckrodt; and has individual stocks or stock options in SilkTech Biopharmaceuticals.
Stephen C. Pflugfelder, MD, is a consultant for Allergan, Dompé US, Inc, Kala Pharmaceuticals, KOWA Pharmaceuticals America, Inc, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Senju Pharmaceutical Co, Ltd; and is a contracted researcher for Dompé US, Inc, and Novartis Pharmaceuticals Corporation.
Melissa Toyos, MD, is a consultant for Bausch & Lomb Incorporated, Mallinckrodt, and RVL Pharmaceuticals, Inc; is a contracted researcher for Allysta Pharmaceuticals, Inc, Bausch & Lomb Incorporated, GreenLight Medicines, Lumenis, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau for Bausch & Lomb Incorporated, Mallinckrodt, and RVL Pharmaceuticals, Inc.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Kurt Brubaker is a consultant for Aquinas Leadership Group, Lexitas Pharma Services, and 2e/Fire and Rain.
COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 83127-TD (Asynchronous)
COPE Course Category: Treatment & Management of Ocular Disease
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.
The content of this COPE-Accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.
©2023 MedEdicus LLC. 270.2
- 1.50 COPE